GlassScriptPhysician profile
Regina Click
NPI 1871879171
$1,578.13
in general payments reported to CMS, 2019-2025
18 companies · $632 in 2025
The $632 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $239 · 2023: $309 · 2024: $398 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,338.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $305.96 | 2022-2025 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.20 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $165.52 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $141.22 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Neurocrine Biosciences, INC. | $119.13 | 2025 | |
| Abbvie INC. | $114.02 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.78 | 2022-2023 | |
| Pfizer INC. | $72.04 | 2024-2025 | |
| Amgen INC. | $68.46 | 2022-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $59.03 | 2025 | |
| Astellas Pharma US INC | $58.19 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $55.56 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.81 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $28.64 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Otsuka America Pharmaceutical, INC. | $24.75 | 2025 | Rexulti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $18.87 | 2024 | Gvoke Hypopen |
| Kerecis Limited | $17.49 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Idorsia Pharmaceuticals US INC | $14.46 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Click listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.